The rewarding/reinforcing effects of cocaine and amphetamines have been thought to be produced, at least in part, by blocking reuptake of dopamine by the dopamine transporter (DAT)and physiologically antagonizing the activities of the vesicular transporter VMAT2. DAT and VMAT2 are the sites that accumulate and sequester each of the dopamine selective toxins that produce the best current experimental models for Parkinsons disease. The DAT gene is expressed in dopaminergic neurons of the ventral midbrain, and serves as the only currently-available marker expressed almost exclusively by these cells, while VMAT2 is expressed in each monoaminergic sell group. During this year, we completed characterization of each of the human DAT gene exonic polymorphisms, and several intronic polymorphisms in several normal and disease. We have made substantial progreaa toward defining each of the polymorphisms in each of the VMAT2 exons in smaller groups of humans. Each protein displays two amino acid sequence variants; conservative in DAT and less conservative in VMAT2. Findings of continued strengthening of associations between the 3untranslated region VNTR marker and ADHD in several studies have bee completmented by initial findings that a VMAT2 polmorphism is differentially distributed among amphetamine preferring and amphetamine nonpreferring human research volunteers. interest in regulatory region polymorphisms at this interesting locus. - cocaine amphetamine Parkinson's diseasse ADHD - Human Subjects: Interview, Questionaires, or Surveys Only

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000160-05
Application #
6289590
Study Section
Special Emphasis Panel (MNB)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Yamashita, Motoyasu; Fukushima, Setsu; Shen, Hao-wei et al. (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31:2132-9
Drgon, Tomas; Lin, Zhicheng; Wang, Gene-Jack et al. (2006) Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26:875-89
Lin, Zhicheng; Walther, Donna; Yu, Xiao-Ying et al. (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14:1393-404
Radzius, Aleksandras; Gallo, Joseph; Gorelick, David et al. (2004) Nicotine dependence criteria of the DIS and DSM-III-R: a factor analysis. Nicotine Tob Res 6:303-8
Liu, Qing-Rong; Zhang, Ping-Wu; Lin, Zhicheng et al. (2004) GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem J 377:171-81
Uhl, George R (2004) Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. Neuropharmacology 47 Suppl 1:140-7
Lin, Zhicheng; Zhang, Ping-Wu; Zhu, Xuguang et al. (2003) Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 278:20162-70
Uhl, George R (2003) Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 18 Suppl 7:S71-80
Uhl, George R; Lin, Zhicheng (2003) The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 479:71-82
Hall, F Scott; Sora, I; Uhl, G R (2003) Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28:620-8

Showing the most recent 10 out of 14 publications